A Cringeworthy Month for Marijuana Stocks With Drops of Almost 40%

Difficult times for stocks like Canopy and Aurora Cannabis do not seem to let up with yet another abysmal month for the top pot companies.

| More on:
Volatile market, stock volatility

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

As cannabis stocks continue to experience a massive decline in share prices, it appears the trend will end anytime soon. There are plenty of people tying up their hopes with cannabis stocks.

Some of my fellow fools believe that stocks like Canopy Growth Corp (TSX:WEED)(NYSE:CGC) make an excellent buy right now while the share prices are down.

I agree that if you manage to stock up on shares from Canopy and Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) and if the companies manage to start turning a profit, you stand to gain a lot. The situation right now, however, does not reflect well on the prospects for both Canopy and Aurora.

The companies are both down by almost 40% in just the past month, and the bad times continue.

Aurora Cannabis

Based on the share prices compared month over month, Aurora Cannabis stocks are down 37.50% at writing. On November 15, 2019, ACB announced its fiscal first-quarter results of 2020 (with the year ending in June).

A net income of $70.8 million in this time is well below consensus estimates of more than $93 million. Shares of ACB dropped 36.84% in just the past five days from writing.

The gross profit before the fair-value adjustments in the quarter ending in September 2019 stood at $42.5 million. At 56.5% of the total revenue, the gross profit was still better than 53% from the same period in the last year. The gross margin increased as ACB successfully lowered production costs by 25% to bring it down to $0.85 per gram.

Canopy Growth

In the September quarter for fiscal 2020, Canopy Growth reported sales of $76.6 million. A bit of a positive sign, it is a year-over-year growth of 228% compared to the same period last year. The earnings per share for Canopy improved from -$1.52 to -$1.08.

The revenue of $76.6 million was an improvement from the same period in the past year, but not as good as expected. Analysts pegged Canopy to post sales of more than $108 million and earnings per share of -$0.39 in Q1 2020. The expectations and actual earnings and revenue were far from what the marijuana industry expected and needs right now.

Foolish takeaway

If you are a potential cannabis investor or a former one, I do have a bit to offer in terms of what you could take away from this. At the time of this writing, Canopy shares are trading for $18.78, while ACB is trading for a flat $3.00 per share. The stocks are down 29.32% and 37.50% month over month amid continuing decline.

Canopy is restructuring charge. The company is introducing new retail pricing architecture, a rationalized package assortment, and improving its marketing strategy to deal with the lower demand and rising inventory levels.

ACB and Canopy are relying on Cannabis 2.0 and products for both companies to hit the retail markets mid-December. The sales could create the turnaround that the marijuana industry needs.

I would say that if things turn out well when the products hit the retail markets, profitability could be on the distant horizon for both Canopy and ACB. I would not advise keeping all your eggs in these two baskets.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Adam Othman has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »